Skip to content
Life Sciences Series B Founded 2001

NovaScan

Developer of diagnostic platform technology for cancer detection. The proprietary impedance-based platform technology for the detection of cancers. The company has developed a single impedance parameter that differs markedly between healthy and cancer tissue, called the Cole Relaxation Frequency. The company was founded in 2001 and headquartered in Milwaukee, United States. It has raised $8.8M in series b funding,…

📍 Milwaukee, United States · Genomics,

Funding snapshot

Last roundSeries B
Amount$671K
Date28 April 2026
Total raised$9M
Team size14

About

Developer of diagnostic platform technology for cancer detection. The proprietary impedance-based platform technology for the detection of cancers. The company has developed a single impedance parameter that differs markedly between healthy and cancer tissue, called the Cole Relaxation Frequency. The company was founded in 2001 and headquartered in Milwaukee, United States. It has raised $8.8M in series b funding, with backing from Builders VC, Gore Range Capital, ChinaBio Partnering Forum, Dipalo Ventures, and others. The company operates in the Life Sciences - Genomics, Life Sciences - Oncology space. Its offerings span Oncology - In-Vitro Diagnostic Tests - Diversified. The company leverages advanced technology to deliver innovative solutions tailored to its target market, addressing key industry challenges and driving value for its customers.

Business model

Oncology > In-Vitro Diagnostic Tests > Diversified,

Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Precision Medicine > Oncology

Institutional investors

Builders VC Gore Range Capital ChinaBio Partnering Forum Dipalo Ventures HBS Alumni Angels Chicago Stateline Angels National Science Foundation Aurora Venture Capital Green Park & Golf Ventures Standing Oak Venture Partners

Latest coverage

No articles yet.

Raising like NovaScan?

Analyze your pitch deck before your next raise.

Analyze My Deck →